FDA approves Trodelvy, the first treatment for metastatic triple-negative breast cancer shown to improve progression-free survival and overall survival.- Gilead Sciences

Gilead Sciences, Inc. announced that the FDA has granted full approval to Trodelvy (sacituzumab govitecan-hziy) for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. The approval is supported by data from the Phase III ASCENT study, in which Trodelvy demonstrated a statistically significant and clinically meaningful 57% reduction in the risk of disease worsening or death (progression-free survival (PFS)), extending median PFS to 4.8 months from 1.7 months with chemotherapy (HR: 0.43; 95% CI: 0.35-0.54; p<0.0001). trodelvy also extended median overall survival (os) to 11.8 months vs. 6.9 months (hr: 0.51; 95% ci: 0.41-0.62; p><0.0001), representing a 49% reduction in the risk of death. trodelvy is directed to the trop-2 receptor, a protein frequently expressed in multiple types of epithelial tumors, including tnbc, where high expression is associated with poor survival and relapse. prior to the fda approval of trodelvy, patients with previously treated metastatic tnbc had few treatment options in this high unmet-need setting. the fda granted accelerated approval to trodelvy in april 2020 based on objective response rate and duration of response results in a phase 1 ii study. this approval expands the previous trodelvy indication to include treatment in adult patients with unresectable locally advanced or metastatic tnbc who have received two or more prior systemic therapies, at least one of them for metastatic disease. regulatory submissions for trodelvy in metastatic tnbc have been filed in the united kingdom, canada, switzerland and australia as part of project orbis, an initiative of the fda oncology center of excellence (oce) that provides a framework for concurrent submission and review of oncology products among international partners, as well as in singapore through our partner everest medicines.the european medicines agency has also validated a marketing authorization application for trodelvy in the european union. all filings are based on data from the phase iii ascent study.>